Company intelligence / Profile preview

Andapta

Seattle, Washington, United States

Ownership: Private
Employees: ~750
Development stage: Other

Overview

Adaptive Biotechnologies has commercialized next-generation sequencing-based assays such as clonoSEQ for minimal residual disease detection in blood cancers. The company’s immunoSEQ technology is widely used in research and clinical trials to decode the adaptive immune system. Recent clinical results include expanded Medicare coverage of clonoSEQ and new product launches in 2025.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeDiagnostic assaymRNA-based drugsAntibody
Industry: Molecular Diagnostics

Partnerships

NeoGenomicspharma partners for drug discovery using immune profiling platforms

Beyond the preview

Go deeper on Andapta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Andapta.

Explore the full profile